{"id":30,"date":"2016-07-29T13:47:37","date_gmt":"2016-07-29T13:47:37","guid":{"rendered":"http:\/\/labs.icahn.mssm.edu\/campbell-lab\/?page_id=30"},"modified":"2016-07-29T13:47:37","modified_gmt":"2016-07-29T13:47:37","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"<p>To learn more about our clinical trials please go to:<\/p>\n<p><a href=\"http:\/\/icahn.mssm.edu\/research-portal\/clinical-trials\">http:\/\/icahn.mssm.edu\/research-portal\/clinical-trials<\/a><\/p>\n<p>Efficacy and Safety of Sparsentan (RE-021) A Dual Endothelin Receptor and Angiotensin Receptor Blocker In Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized Double-Blind Active-Control Dose-Escalation Study<br \/>\nThe purpose of this study is to collect information about the possible effects of Sparsentan to treat the urine protein loss in patients with FSGS (Focal Segmental Glomerulosclerosis) as well as other positive and negative effects of the treatment. In this study the sponsor Retro&#8230;<\/p>\n<p>A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis<br \/>\nThe purpose of this study is to see if anifrolumab may have an effect in treating lupus nephritis, to see how well it is tolerated, and to measure levels of anifrolumab in the blood. Subjects may qualify to take part in this research study because they have lupus nephritis&#8230;.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>To learn more about our clinical trials please go to: http:\/\/icahn.mssm.edu\/research-portal\/clinical-trials Efficacy and Safety of Sparsentan (RE-021) A Dual Endothelin Receptor and Angiotensin Receptor Blocker In Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized Double-Blind Active-Control Dose-Escalation Study The purpose of this study is to collect information about the possible effects of Sparsentan to treat [&hellip;]<\/p>\n","protected":false},"author":189,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-30","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/pages\/30","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/users\/189"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/comments?post=30"}],"version-history":[{"count":1,"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/pages\/30\/revisions"}],"predecessor-version":[{"id":31,"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/pages\/30\/revisions\/31"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/campbell-lab\/wp-json\/wp\/v2\/media?parent=30"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}